Solvemate Enables Greater Customer Inclusiveness with Enhanced Accessibility Features
23.11.2021 12:06:00 EET | Business Wire | Press release
Conversational AI for Customer Service leader Solvemate today announces the availability of improved accessibility for its customer service automation platform. Solvemate accessibility helps customer service teams extend the use of self-service to those with impairments so all customers can find instant answers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005628/en/
Solvemate Conversational AI for customer service helps those with impairments have meaningful conversations with automation.
Improving the Customer Service Experience for Everyone
According to the World Health Organization, over 1 billion people live with some form of disability. Inclusion is an imperative that should be built into every company’s strategy. Accessibility is also an important aspect of the service experience to drive customer satisfaction and loyalty.
Modern customer service chatbots using Artificial Intelligence (AI) already offer enhanced digital accessibility and usability. Conversational AI chatbots extract insights and patterns from data to identify and propose the most logical answers to end users. Customers then solve their problem in the fewest number of interactions. Modern chatbots offer the right knowledge at the right time in a condensed manner which helps people with cognitive disabilities in a way that an extensive FAQ page can not.
Solvemate’s customer service automation platform is now more accessible to people with sight, hearing, visual and mobility impairments. Solvemate is Web Content Accessibility Guidelines (WCAG) 2.2 compliant.
Solvemate’s enhanced accessibility features include:
-
For those with cognitive impairments:
- The Solvemate Contextual Conversation Engine™ uniquely uses both dynamic decision tree logic buttons and free text fields (NLP)
-
For those with hearing impairments:
- Solvemate’s chatbot includes text and image conversation descriptions to read along as well as a text-based handover
-
For those with mobility impairments:
- Solvemate's Conversational IVR ( voice) allows intuitive access to customers service via phone
-
For those with visual impairments:
- Solvemate widget can be fully navigated with screen readers
No Additional Work for Customer Service Teams
Solvemate’s accessibility feature works out of the box with no extra effort for the service team setting up the chatbot. Teams can instantly extend their service offering to more customers with personalized, self-service automation.
Jürgen Vogel, co-founder and CTO of Solvemate, comments: “Providing accessibility for those that need additional support is an imperative for all customer service teams. We see this across all sectors, particularly banking and public institutions that need to make services equitably available to all users.”
Read more about why chatbots are key to customer service accessibility.
Learn more at solvemate.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005628/en/
Contact information
Press Contact:
Sylvia Jensen
s.jensen@solvemate.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom